Drug updated on 10/28/2024
| Dosage Form | Opthalmic solution (topical; netarsudil 0.2 mg/mL [0.02%] and latanoprost 0.05 mg/mL [0.005%]) |
| Drug Class | Rho kinase inhibitors and prostaglandin F2α analogues |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Latest News
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Rocklatan (netarsudil and latanoprost ophthalmic solution) Prescribing Information. | 2023 | Aerie Pharmaceuticals, Inc., Irvine, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Comparison of netarsudil/Latanoprost therapy with latanoprost monotherapy for lowering intraocular pressure: A systematic review and meta-analysis. | 2022 | Korean Journal of Ophthalmology |
| Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials. | 2022 | Frontiers in Medicine |
| Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension. | 2022 | The Cochrane Database of Systematic Reviews |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension. Technology appraisal guidance number TA1009. | 2024 | National Institute for Health and Care Excellence |
| Guidelines for the management of open-angle glaucoma: National Program Area Eye Diseases, National Working Group Glaucoma. | 2024 | Acta Ophthalmologica |